Literature DB >> 12117892

Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.

M Longo1, A Crosignani, P M Battezzati, C Squarcia Giussani, P Invernizzi, M Zuin, M Podda.   

Abstract

BACKGROUND: Primary biliary cirrhosis (PBC), a chronic cholestatic liver disease, is frequently associated with severe hypercholesterolaemia but the clinical significance of this finding is unclear. AIMS: To characterise changes in serum lipid profile over time and to assess the risk of cardiovascular disease in PBC. SUBJECTS AND METHODS: We studied a cohort of 400 PBC patients for 6.2 years (range 4 months to 24 years) by serial determinations of serum lipid levels and registration of all cardiovascular events. Subjects included in an Italian prospective population based study served as controls.
RESULTS: At presentation, 76% of patients had serum cholesterol levels >5.2 mmol/l. Hyperbilirubinaemic patients had higher total cholesterol and lower high density lipoprotein (HDL) cholesterol levels (p<0.001). With time, disease progression was associated with a reduction in total (p<0.001) and HDL (p<0.05) cholesterol. The incidence of cardiovascular events was similar to that of the general population (cerebrovascular events: standardised ratio 1.4; 95% confidence interval 0.5-3.7; coronary events: 2.2; 0.9-4.3). Hypertension was associated with an increased risk of cardiovascular events (3.8; 1.6-8.9). Association with moderate hypercholesterolaemia was of borderline significance (3.8; 0.9-17) whereas severe hypercholesterolaemia was not associated with increased risk (2.4, 0.5-11).
CONCLUSIONS: In PBC, serum cholesterol levels markedly increase with worsening of cholestasis, and decrease in the late disease stages, despite a severe reduction in biliary secretion. Marked hypercholesterolaemia, typical of severe longstanding cholestasis, is not associated with an excess risk of cardiovascular disease while less advanced patients with moderate hypercholesterolaemia are exposed to an increased cardiovascular risk. Putative protective factors in PBC patients with severe hypercholesterolaemia should be assessed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117892      PMCID: PMC1773333          DOI: 10.1136/gut.51.2.265

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  The hypercholesterolaemia of obstructive jaundice.

Authors:  N McIntyre; D S Harry; A J Pearson
Journal:  Gut       Date:  1975-05       Impact factor: 23.059

3.  Lecithin--cholesterol acyltransferase and the lipoprotein abnormalities of obstructive jaundice.

Authors:  J Agorastos; C Fox; D S Harry; N McIntyre
Journal:  Clin Sci Mol Med       Date:  1978-04

4.  Clinical biostatistics. XLVIII. Efficacy of different research structures in preventing bias in the analysis of causation.

Authors:  A R Feinstein
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

5.  Mechanisms of action of cholestyramine in the treatment of hypercholesterolemia.

Authors:  D J Nazir; L Horlick; B J Kudchodkar; H S Sodhi
Journal:  Circulation       Date:  1972-07       Impact factor: 29.690

6.  The epidemiology of cancer therapy. II. The clinical course: data, decisions, and temporal demarcations.

Authors:  A R Feinstein; J A Pritchett; C R Schimpff
Journal:  Arch Intern Med       Date:  1969-03

7.  Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification.

Authors:  C E Jahn; E J Schaefer; L A Taam; J H Hoofnagle; F T Lindgren; J J Albers; E A Jones; H B Brewer
Journal:  Gastroenterology       Date:  1985-12       Impact factor: 22.682

8.  Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration.

Authors:  M Del Puppo; M Galli Kienle; A Crosignani; M L Petroni; B Amati; M Zuin; M Podda
Journal:  J Lipid Res       Date:  2001-03       Impact factor: 5.922

9.  Lipid absorption, bile acids, and cholesterol metabolism in patients with chronic liver disease.

Authors:  T A Miettinen
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

10.  Serum bilirubin: a prognostic factor in primary biliary cirrhosis.

Authors:  J M Shapiro; H Smith; F Schaffner
Journal:  Gut       Date:  1979-02       Impact factor: 23.059

View more
  53 in total

1.  Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.

Authors:  M Allocca; A Crosignani; A Gritti; G Ghilardi; D Gobatti; D Caruso; M Zuin; M Podda; P M Battezzati
Journal:  Gut       Date:  2006-04-21       Impact factor: 23.059

2.  Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.

Authors:  M I Prince; A Chetwynd; W L Craig; J V Metcalf; O F W James
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

3.  Assessment of metabolic syndrome in patients with primary biliary cirrhosis.

Authors:  Tamara Alempijevic; Aleksandra Sokic-Milutinovic; Aleksandra Pavlovic Markovic; Rada Jesic-Vukicevic; Biljana Milicic; Djuro Macut; Dragan Popovic; Dragan Tomic
Journal:  Wien Klin Wochenschr       Date:  2012-04-25       Impact factor: 1.704

4.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Authors:  Fernanda Q Onofrio; Gideon M Hirschfield; Aliya F Gulamhusein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

5.  Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort.

Authors:  D E J Jones; N Bhala; J Burt; J Goldblatt; M Prince; J L Newton
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

Review 6.  Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis.

Authors:  Vasiliy Ivanovich Reshetnyak
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

7.  Increased hepatic ABCA1 transporter is associated with hypercholesterolemia in a cholestatic rat model and primary biliary cholangitis patients.

Authors:  Yasuaki Takeyama; Yuko Uehara; Akira Anan; Daisuke Morihara; Keiji Yokoyama; Kazuhide Takata; Takashi Tanaka; Makoto Irie; Kaoru Iwata; Satoshi Shakado; Tetsuro Sohda; Shotaro Sakisaka
Journal:  Med Mol Morphol       Date:  2017-06-28       Impact factor: 2.309

Review 8.  Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications.

Authors:  Katriina Nemes; Fredrik Åberg; Helena Gylling; Helena Isoniemi
Journal:  World J Hepatol       Date:  2016-08-08

9.  Fenofibrate in primary biliary cirrhosis: a pilot study.

Authors:  E N Liberopoulos; M Florentin; M S Elisaf; D P Mikhailidis; E Tsianos
Journal:  Open Cardiovasc Med J       Date:  2010-04-28

10.  Use of statins in patients with liver disease.

Authors:  Sweta Tandra; Raj Vuppalanchi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.